NRIX EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
NRIX's ev/ebitda is higher than 95% of the last 10 years.
EV/EBITDA History
NRIX EV/EBITDA by year
Yearly range of NRIX’s ev/ebitda from 2026 to 2026. Over the full period it ranged from 5.9 to 7.8, averaging 6.9.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 5.9 | 6.9 | 7.8 | 7.7 |
Get notified when NRIX EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is NRIX EV/EBITDA High or Low Right Now?
Nurix Therapeutics, Inc.'s EV/EBITDA is currently 7.7, which is near historic high relative to its 10-year historical range. The 10-year median EV/EBITDA for NRIX is approximately 7.0. See all NRIX valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.